Mucus mucopolysaccharides (MPS)

Mucus mucopolysaccharides, a term encompassing both mucins (large glycoproteins) and glycosaminoglycans (GAGs), are the primary structural constituents of the protective mucus layer that lines the respiratory, gastrointestinal, and urogenital tracts (CABI Digital Library, 2023). These molecules form a complex, viscoelastic gel that serves as a critical physiological barrier against mechanical injury, chemical irritation (such as gastric acid), and microbial invasion (ResearchGate, 2026). In the respiratory system, they facilitate mucociliary clearance, while in the stomach, they contribute to the mucus-bicarbonate barrier that prevents autodigestion of the gastric mucosa (PLOS One, 2026). The clinical significance of mucus mucopolysaccharides is highlighted in diseases characterized by their dysregulation, such as cystic fibrosis and chronic obstructive pulmonary disease (COPD), where hyperviscous mucus leads to airway obstruction and chronic infection. Conversely, a deficiency in the gastric mucus layer is a key factor in the development of peptic ulcers (ResearchGate, 2023). Pharmacological interventions target these molecules through various mechanisms: mucolytics like N-acetylcysteine reduce mucus viscosity by breaking disulfide bonds in mucin polymers, while cytoprotective agents like sucralfate bind to the mucus-protein complex to reinforce the epithelial barrier. Furthermore, the pathological accumulation of these substances due to genetic enzyme deficiencies results in mucopolysaccharidoses, which are treated with enzyme replacement therapies (NIH, 2022).

Other names

GlycosaminoglycansMucinsMucoid substancesAcid mucopolysaccharidesMucosubstancesMucopolysaccharides

Reduction of disulfide bonds in mucin polymers, hydrolysis of extracellular DNA, stimulation of surfactant/mucus production, and physical adherence to mucosal lesions to enhance barrier integrity.